Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + Bendamustine in Mature B-cell Lymphoma
NCT06415708Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), Hairy cell leukemia variant (HCL-V), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Nov 2023; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)Waldenström macroglobulinemia (WM)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on NCT06415708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415708.